Clinical trials
Locally Advanced Lung Non-Small Cell Carcinoma clinical trials
Below are recruiting locally advanced lung non-small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 254 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT04270591RecruitingPhase 1/Phase 2
Glumetinib for lung cancer with MET changes
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Louisville, KentuckyAges 18–80 - NCT05334277RecruitingPhase 2
Test furmonertinib for advanced EGFR-mutant lung cancer
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
ChangchunAges 18 years+ - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT05777278RecruitingPhase 1/Phase 2
Savolitinib plus docetaxel for advanced lung cancer with high MET
This trial studies savolitinib (an oral MET-targeted medicine) combined with docetaxel (an IV chemotherapy) in people with advanced non-small cell lung cancer (NSCLC) whose tumor has high MET activity. It’s designed to see if this combination can shrink tumors or control the cancer after the first standard treatment.
Guangzhou, GuangdongAges 18 years+ - NCT05382728RecruitingPhase 3
Test drug for EGFR-mutant lung cancer without prior treatment
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Changsha, HunanAges 18–80 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06020430Recruiting
Skipping routine radiation for advanced lung cancer after immunotherapy and chemo
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
Wuhan, HubeiAges 18–75 - NCT06361784Recruiting
Heart-Sparing Radiation for Stage 3 Lung Cancer
This study tests a new way of planning radiation therapy for stage 3 lung cancer. By carefully mapping the heart's structure, doctors aim to protect it from radiation and improve treatment safety.
MilanAges Any age - NCT04680377Recruiting
Using gut microbes to predict durvalumab side effects in lung cancer
This study looks at the microbiome (the tiny organisms in your gut) to try to predict who will get side effects from durvalumab after chemoradiation. If you join, your care team will use your microbiome results to help understand toxicity risk and improve future treatment planning.
Kansas City, KansasAges 18 years+ - NCT07830342RecruitingPhase 1
Study of tumor-infiltrating lymphocyte therapy for advanced non-small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
ShanghaiAges 18–75 - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+ - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Maumee, OhioAges 18 years+ - NCT06517953RecruitingPhase 2
Testing two targeted pills for rare EGFR lung cancer
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07793500RecruitingEarly Phase 1
Nebulized drug for lung metastases from solid tumors
This study tests a new drug given as a mist you breathe in, for people whose cancer has spread to the lungs. The goal is to see if it can shrink tumors or slow their growth.
BeijingAges 18–75 - NCT07784959RecruitingPhase 1
Study of NXP900 with lorlatinib for ALK-positive lung cancer
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
Fairfax, VirginiaAges Any age - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75 - NCT07754409Recruiting
Quality of life during lung cancer treatment with immunotherapy
This study looks at how patients with advanced lung cancer feel during their treatment, which combines chemotherapy, radiation, and an immunotherapy drug. The goal is to understand and improve quality of life during therapy.
GothenburgAges 18 years+ - NCT05014464RecruitingPhase 2
Testing ALK-targeted pills for ALK-positive advanced squamous cancer
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Changsha, HunanAges 18 years+ - NCT05501665RecruitingPhase 1/Phase 2
Adaptive radiation plus pembrolizumab for stage IV lung cancer
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
Nashville, TennesseeAges 18 years+ - NCT07697586RecruitingPhase 2
Two new drugs for advanced lung cancer without EGFR or ALK
This trial tests a combination of two new drugs, SKB264 and SKB118, for people with advanced non-small cell lung cancer. It may be an option if your cancer does not have the EGFR or ALK gene changes and you are in relatively good health.
Jilin CityAges 18–75 - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT07669779RecruitingPhase 2
Study of AK146D1 and AK112 for advanced lung cancer
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75
Hear when a new Locally Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Locally Advanced Lung Non-Small Cell Carcinoma trials by city
Studies with a site in or near these metro areas.
Locally Advanced Lung Non-Small Cell Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for locally advanced lung non-small cell carcinoma?
- Yes. Clin2 currently lists 254 recruiting locally advanced lung non-small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced lung non-small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced lung non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Lung Non-Squamous Non-Small Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.